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✉

The neurologic manifestations of acute COVID-19 are well characterized, but a comprehensive evaluation of postacute neurologic
sequelae at 1 year has not been undertaken. Here we use the national healthcare databases of the US Department of Veterans
Affairs to build a cohort of 154,068 individuals with COVID-19, 5,638,795 contemporary controls and 5,859,621 historical controls;
we use inverse probability weighting to balance the cohorts, and estimate risks and burdens of incident neurologic disorders at
12 months following acute SARS-CoV-2 infection. Our results show that in the postacute phase of COVID-19, there was increased
risk of an array of incident neurologic sequelae including ischemic and hemorrhagic stroke, cognition and memory disorders,
peripheral nervous system disorders, episodic disorders (for example, migraine and seizures), extrapyramidal and movement
disorders, mental health disorders, musculoskeletal disorders, sensory disorders, Guillain–Barré syndrome, and encephalitis or
encephalopathy. We estimated that the hazard ratio of any neurologic sequela was 1.42 (95% confidence intervals 1.38, 1.47) and
burden 70.69 (95% confidence intervals 63.54, 78.01) per 1,000 persons at 12 months. The risks and burdens were elevated even
in people who did not require hospitalization during acute COVID-19. Limitations include a cohort comprising mostly White males.
Taken together, our results provide evidence of increased risk of long-term neurologic disorders in people who had COVID-19.

L

ong COVID—the umbrella term describing the constellation
of postacute sequelae following infection with SARS-CoV-2—
can involve a broad array of extrapulmonary organ dysfunction1 including several structural neurologic abnormalities2. To
date, most studies examining postacute COVID-19 clinical neurologic disorders were limited to people who were hospitalized during
the acute phase of COVID-19, and all studies had follow-up duration of less than 6 months with a narrow selection of neurologic
outcomes3–8. A comprehensive evaluation of postacute COVID-19
neurologic outcomes at 12 months is needed but has not yet been
undertaken. Studies of postacute COVID-19 neurologic outcomes
across the care-setting spectrum of the acute phase of the disease
(nonhospitalized, hospitalized and admitted to intensive care) are
also not yet available. Addressing this knowledge gap is important
in helping guide postacute COVID-19 care strategies and healthcare
system capacity planning.
Here we leverage the breadth and depth of the US Department
of Veterans Affairs national healthcare databases to build a cohort
of 154,068 people who survived the first 30 days of COVID-19 and
two control groups: a contemporary cohort consisting of 5,638,795
users of the US Department of Veterans Health Care System (VHA)
with no evidence of SARS-CoV-2 infection, and a historical cohort
(predating the global COVID-19 pandemic) consisting of 5,859,621
VHA users during 2017. We employed a longitudinal observational
study design and used inverse probability weighting to balance the
cohorts, and estimated the risks and burdens at 12 months of a set of
prespecified neurologic outcomes in the overall cohort and by care
setting of the acute phase of COVID-19 (nonhospitalized, hospitalized and admitted to intensive care).

Results

There were 154,068, 5,638,795 and 5,859,621 participants in
the COVID-19, the contemporary control and the historical
control groups, respectively (Fig. 1). Median follow-up time in the

COVID-19, contemporary control and historical control groups
was 408 (interquartile range: 378–500), 409 (379–505) and 409
(379–504) days, respectively. The COVID-19, contemporary control
and historical control groups had 185,399, 6,808,464 and 7,071,123
person-years of follow up, respectively; altogether corresponding to
14,064,985 person-years of follow up.
The demographic and health characteristics of the COVID-19,
the contemporary control and historical control groups before and
after weighting are presented in Supplementary Tables 1 and 2,
respectively.
Incident neurologic outcomes in COVID-19 versus contemporary control. We used the inverse probability weighting method
to balance the COVID-19 and the contemporary control groups;
examination of standardized mean differences of demographic
and health characteristics after weighting suggested good balance
(Extended Data Fig. 1).
We estimated the risks of a set of prespecified neurologic outcomes in COVID-19 versus the contemporary control group; we
also estimated the adjusted excess burden of neurologic outcomes
due to COVID-19 per 1,000 persons at 12 months on the basis of the
difference between the estimated incidence rate in the COVID-19
and contemporary control groups. Risks and burdens of individual
neurologic outcomes are provided in Fig. 2 and Supplementary
Table 3 and are discussed below. Risks and burdens of the composite
endpoints are provided in Fig. 3 and Supplementary Table 3.
Cerebrovascular disorders. People who survived the first 30 days
of COVID-19 exhibited increased risk of ischemic stroke (HR
1.50 (1.41, 1.61); burden 3.40 (2.75, 4.09) per 1,000 persons at 12
months; for all HRs and burdens, parenthetical ranges refer to 95%
confidence intervals (CIs)), transient ischemic attacks (TIAs) (HR
1.62 (1.50, 1.75); burden 2.03 (1.64, 2.46)), hemorrhagic stroke
(HR 2.19 (1.63, 2.95); burden 0.21 (0.11, 0.35)) and cerebral venous
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Fig. 1 | Cohort construction flowchart. Cohort construction for COVID-19 group (blue), contemporary control group (orange) and historical control group
(pink). Comparisons between groups are presented in green.

thrombosis (HR 2.69 (1.29, 5.62); burden 0.05 (0.01, 0.14)). The risk
and burden of a composite of these cerebrovascular outcomes were
1.56 (1.48, 1.64) and 4.92 (4.26, 5.62), respectively.

(1.24, 1.77)); burden 0.32 (0.16, 0.51)). The respective risk and burden of a composite of these disorders of peripheral nerves were 1.34
(1.29, 1.39) and 8.64 (7.44, 9.87).

Cognition and memory. There were increased risks of memory
problems (HR 1.77 (1.68, 1.85); burden 10.07 (9.00, 11.20)) and
Alzheimer’s disease (HR 2.03 (1.79, 2.31); burden 1.65 (1.27, 2.10)).
The risk and burden of a composite of these cognition and memory
outcomes were 1.80 (1.71, 1.88) and 10.35 (9.27, 11.47), respectively.

Episodic disorders. Episodic disorders included migraine (HR 1.21
(1.14, 1.28); burden 2.04 (1.36, 2.76)), epilepsy and seizures (HR
1.80 (1.61, 2.01); burden 2.01 (1.47, 2.63)) and headache disorders
(HR 1.35 (1.25, 1.45); burden 1.46 (1.06, 1.89)). The risk and burden
of a composite of these episodic disorders were 1.32 (1.26, 1.39) and
4.75 (3.79, 5.76), respectively.

Disorders of peripheral nerves. These included peripheral neuropathy (HR 1.34 (1.28, 1.40); burden 5.64 (4.67, 6.65)), paresthesia
(HR 1.32 (1.25, 1.39); burden 2.89 (2.27, 3.55)), dysautonomia (HR
1.30 (1.21, 1.40); burden 1.60 (1.12, 2.12)) and Bell’s palsy (HR 1.48

Extrapyramidal and movement disorders. These included abnormal
involuntary movements (HR 1.41 (1.32, 1.50); burden 2.85 (2.24,
3.49)), tremor (HR 1.37 (1.25, 1.51); burden 1.10 (0.73, 1.51)),
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Fig. 2 | Risks and 12-month burdens of incident postacute COVID-19 neurologic outcomes compared with the contemporary control cohort. Outcomes
were ascertained 30 days after the COVID-19-positive test until the end of follow up. COVID-19 cohort (n = 154,068) and contemporary control cohort
(n = 5,638,795). Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess burdens (bars) and 95% CIs (error bars). Burdens
are presented per 1,000 persons at 12 months of follow up. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00
indicate significantly increased risk.

Parkinson-like disease (HR 1.50 (1.28, 1.75); burden 0.89 (0.50,
1.34)), dystonia (HR 1.57 (1.29, 1.90); burden 0.40 (0.21, 0.63)) and
myoclonus (HR 1.42 (1.13, 1.79); burden 0.14 (0.04, 0.26)). The
respective risk and burden of a composite of these extrapyramidal
and movement disorders were 1.42 (1.34, 1.50) and 3.98 (3.24, 4.77).
2408

Mental health disorders. Mental health disorders included major
depressive disorders (HR 1.44 (1.39, 1.48); burden 17.28 (15.43,
19.18)), stress and adjustment disorders (HR 1.39 (1.34, 1.44); burden 14.34 (12.66, 16.07)), anxiety disorders (HR 1.38 (1.33, 1.42);
burden 12.44 (10.93, 13.99)) and psychotic disorders (HR 1.51
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Fig. 3 | Risks and 12-month burdens of incident postacute COVID-19 composite neurologic outcomes compared with the contemporary control cohort.
Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke and cerebral venous thrombosis), cognition and
memory (memory problems and Alzheimer’s disease), disorders of the peripheral nerves (peripheral neuropathy, paresthesia, dysautonomia and Bell’s
palsy), episodic disorders (migraine, epilepsy and seizures and headache disorders), extrapyramidal and movement disorders (abnormal involuntary
movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress and adjustment disorders,
anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia and myopathy), sensory disorders (hearing abnormalities or
tinnitus, vision abnormalities, loss of smell and loss of taste), other neurologic or related disorders (dizziness, somnolence, Guillain–Barré syndrome,
encephalitis or encephalopathy and transverse myelitis) and any neurologic outcome (incident occurrence of any neurologic outcome studied). Outcomes
were ascertained 30 days after the COVID-19-positive test until the end of follow up. The COVID-19 cohort had n = 154,068 and the contemporary control
cohort had n = 5,638,795. Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess burdens (bars) and 95% CIs (error bars).
Burdens are presented per 1,000 persons at 12 months of follow up. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than
1.00 indicate significantly increased risk.

(1.33, 1.71); burden 1.02 (0.66, 1.43)). The respective risk and burden of a composite of these mental health disorders were 1.43 (1.38,
1.47) and 25.00 (22.40, 27.69).
Musculoskeletal disorders. Musculoskeletal disorders included joint
pain (HR 1.34 (1.31, 1.38); burden 27.65 (25.01, 30.35)), myalgia
(HR 1.83 (1.77, 1.90); burden 15.97 (14.75, 17.23)) and myopathy
(HR 2.76 (2.30, 3.32); burden 0.71 (0.52, 0.93)). The risk and burden
of a composite of these musculoskeletal disorders were 1.45 (1.42,
1.48) and 40.09 (37.22, 43.01), respectively.
Sensory disorders. Sensory disorders included hearing abnormalities or tinnitus (HR 1.22 (1.18, 1.25); burden 11.87 (10.05, 13.75)),
vision abnormalities (HR 1.30 (1.24, 1.36); burden 5.59 (4.55,

6.68)), loss of smell (HR 4.05 (3.45, 4.75)); burden 1.07 (0.86, 1.32))
and loss of taste (HR 2.26 (1.54, 3.32); burden 0.11 (0.05, 0.21)). The
respective risk and burden of a composite of these sensory disorders
were 1.25 (1.22, 1.28) and 17.03 (14.85, 19.26).
Other neurologic or related disorders. These included dizziness (HR
1.44 (1.38, 1.50); burden 6.65 (5.72, 7.61)), somnolence (HR 1.67
(1.31, 2.12); burden 0.56 (0.26, 0.94)), Guillain–Barré syndrome
(HR 2.16 (1.40, 3.35); burden 0.11 (0.04, 0.22)), encephalitis or
encephalopathy (HR 1.82 (1.16, 2.84); burden 0.07 (0.01, 0.16) and
transverse myelitis (HR 1.49 (1.11, 2.00); burden 0.03 (0.00, 0.11)).
The respective risk and burden of a composite of these other neurologic or related disorders were 1.46 (1.40, 1.52) and 7.37 (6.41,
8.38), respectively.
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Fig. 4 | Subgroup analyses of the risks of incident postacute COVID-19 composite neurologic outcomes compared with the contemporary control cohort.
Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke and cerebral venous thrombosis), cognition and
memory (memory problems and Alzheimer’s disease) disorders, disorders of the peripheral nerves (peripheral neuropathy, paresthesia, dysautonomia and
Bell’s palsy), episodic disorders (migraine, epilepsy and seizures, and headache disorders), extrapyramidal and movement disorders (abnormal involuntary
movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress and adjustment disorders,
anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia and myopathy), sensory disorders (hearing abnormalities or
tinnitus, vision abnormalities, loss of smell and loss of taste), other neurologic or related disorders (dizziness, somnolence, Guillain–Barré syndrome,
encephalitis or encephalopathy and transverse myelitis) and any neurologic outcome (incident occurrence of any neurologic outcome studied). Outcomes
were ascertained 30 days after the COVID-19-positive test until the end of follow up. COVID-19 cohort (n = 154,068) and contemporary control cohort
(n = 5,638,795). Adjusted HRs (dots) and 95% (error bars) CIs are presented. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values
greater than 1.00 indicate significantly increased risk.

Composite outcome of any neurologic disorder. We then examined
the risk and burden of having any neurologic outcome (defined
as the occurrence of any incident prespecified neurologic outcome included in this study). Compared with the contemporary
control group, there was increased risk and burden of any neurologic outcome (HR 1.42 (1.38, 1.47); burden 70.69 (63.54, 78.01)),
respectively.
Subgroup analyses. The risks of incident composite neurologic outcomes were evident in all subgroups based on age, race, sex, obesity,
smoking, area deprivation index (ADI), diabetes, chronic kidney
disease, hyperlipidemia, hypertension and immune dysfunction
(Fig. 4 and Supplementary Table 4). Because of the relatively smaller
size, there was greater variance (and larger CIs) in the female cohort
compared with the male cohort.
Analyses of risk across age as a continuous variable suggest that
the risks of incident composite neurologic outcomes were evident
across the age range in this cohort. Interaction analyses between
age and exposure suggested that the risks of episodic disorders,
mental health disorders, musculoskeletal disorders and any neurologic disorder increased as age increased (P for interaction <0.001,
<0.001 and 0.003, respectively), and risks of cognition and memory
2410

disorders, sensory disorders and other neurologic or related disorders decreased as age increased (P for interaction 0.001, <0.001,
<0.001, respectively) (Extended Data Fig. 2).
Incident neurologic disorders in COVID-19 versus contemporary controls by care setting of the acute infection. We then
examined the risks and burdens of neurologic outcomes in mutually exclusive groups by the care setting of the acute infection
(whether people were nonhospitalized (n = 131,915), hospitalized
(n = 16,764) or admitted to intensive care (n = 5,389) during the
acute phase of COVID-19). The demographic and health characteristics of these three groups before and after weighting are presented in Supplementary Tables 5 and 6, respectively. Assessment
of standardized mean differences after application of inverse
weighting suggested that covariates were well balanced (Extended
Data Fig. 3a).
Compared with the contemporary control group, the risks and
burdens of the prespecified neurologic outcomes were evident
even among those who were not hospitalized during the acute
phase of COVID-19 and increased according to the severity of
the acute infection from nonhospitalized to hospitalized to those
admitted to intensive care (Fig. 5 and Supplementary Table 7);
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Fig. 5 | Risks and 12-month burdens of incident postacute COVID-19 neurologic outcomes compared with the contemporary control cohort by care
setting of the acute infection. Risks and burdens were assessed at 12 months in mutually exclusive groups comprising nonhospitalized individuals with
COVID-19 (green), individuals hospitalized for COVID-19 (orange) and individuals admitted to intensive care for COVID-19 during the acute phase (first
30 days) of COVID-19 (purple). Outcomes were ascertained 30 days after the COVID-19-positive test until the end of follow up. The contemporary control
cohort served as the referent category. Within the COVID-19 cohort, nonhospitalized (n = 131,915), hospitalized (n = 16,764), admitted to intensive care
(n = 5,389) and contemporary control cohort (n = 5,606,761). Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess
burdens (bars) and 95% CIs (error bars). Burdens are presented per 1,000 persons at 12 months of follow up. ICU, intensive care unit. The dashed line
marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.
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results for the composite outcomes are shown in Fig. 6 and
Supplementary Table 7.
Incident neurologic disorders in COVID-19 versus historical
controls. To test the robustness of study results, we evaluated the
associations between COVID-19 and the prespecified neurologic
outcomes in analyses considering a historical control group (from
an era predating the pandemic) as the referent category; the demographic and health characteristics before and after weighting are
presented in Supplementary Tables 1, 2, 8 and 9, examination of
standardized mean differences suggested that covariates were balanced after application of inverse weighting (Extended Data Fig.
3b,c). The results showed increased risks and associated burdens of
the prespecified outcomes in comparisons of COVID-19 versus the
overall historical control group (Extended Data Figs. 4 and 5 and
Supplementary Table 10), in subgroup analyses and by age as continuous variable (Extended Data Fig. 6 and 7 and Supplementary
Table 11) and by care setting of the acute phase of the disease
(Extended Data Figs 8 and 9 and Supplementary Table 12). Both
the direction and magnitude of risks were consistent with analyses
using the contemporary control as the referent category.
Sensitivity analyses. We investigated the robustness of our results
in multiple sensitivity analyses. We tested the association between
COVID-19 and all the composite outcomes in sensitivity analyses
involving comparisons between COVID-19 versus the contemporary control and—separately—COVID-19 versus the historical control, and additionally COVID-19 by care setting of the acute phase of
the infection versus both controls. (1) We tested the results in models specified to include only predefined covariates (that is without
inclusion of any algorithmically selected high-dimensional covariates) to build the inverse probability weighting; (2) we employed
the doubly robust method through application of both weighting
and covariate adjustment in the survival models (instead of the
inverse weighting method used in primary analyses) as an alternative approach to examine the associations between COVID-19 and
the risk of the prespecified neurologic outcomes. The results from
the sensitivity analyses were consistent with those generated using
the primary approach (Supplementary Tables 13a,b and 14a,b).
Positive- and negative-outcome controls. To verify whether our
approach would reproduce established knowledge, we tested fatigue
as a positive outcome control. The results suggested that COVID-19
was associated with increased risk of fatigue in comparison with the
contemporary control and the historical control (Supplementary
Table 15).
To test for potential presence of spurious biases, we subjected
our analytic approach to the examination of a battery of three
negative-outcome controls where no prior knowledge suggests an
association is expected. The results showed no statistically significant
association between COVID-19 and any of the negative-outcome
controls in comparison with the contemporary and the historical
control groups—these results were consistent with pretest expectations (Supplementary Table 15).
Negative-exposure controls. To further test the rigor of our
approach, we examined the associations between a pair of
negative-exposure controls and each of our prespecified outcomes.
We hypothesized that receipt of influenza vaccination in odd- versus even-numbered calendar days between 1 March 2020 and 15
January 2021 would be associated with similar risks of each of the
prespecified neurologic outcomes evaluated in this analysis. We
therefore tested the associations between receipt of the influenza
vaccine in even- (n = 571,291) versus odd- (n = 605,453) numbered
calendar days and each of the prespecified neurologic outcomes.
We used the same data sources, cohort design, analytic approach
2412
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Fig. 6 | Risks and 12-month burdens of incident postacute COVID-19
composite neurologic outcomes compared with the contemporary
control cohort by care setting of the acute infection. Risks and burdens
were assessed at 12 months in mutually exclusive groups comprising
nonhospitalized individuals with COVID-19 (green), individuals hospitalized
for COVID-19 (orange) and individuals admitted to intensive care for
COVID-19 during the acute phase (first 30 days) of COVID-19 (purple).
Composite outcomes consisted of cerebrovascular disorders (ischemic
stroke, TIA, hemorrhagic stroke and cerebral venous thrombosis), cognition
and memory disorders (memory problems and Alzheimer’s disease),
disorders of the peripheral nerves (peripheral neuropathy, paresthesia,
dysautonomia and Bell’s palsy), episodic disorders (migraine, epilepsy
and seizures, and headache disorders), extrapyramidal and movement
disorders (abnormal involuntary movements, tremor, Parkinson-like
disease, dystonia, myoclonus), mental health disorders (major depressive
disorders, stress and adjustment disorders, anxiety disorders, and
psychotic disorders), musculoskeletal disorders (joint pain, myalgia and
myopathy), sensory disorders (hearing abnormalities or tinnitus, vision
abnormalities, loss of smell and loss of taste), other neurologic or related
disorders (dizziness, somnolence, Guillain–Barré syndrome, encephalitis
or encephalopathy and transverse myelitis) and any neurologic outcome
(incident occurrence of any neurologic outcome studied). Outcomes were
ascertained 30 days after the COVID-19-positive test until the end of follow
up. The contemporary control cohort served as the referent category.
Within the COVID-19 cohort were the nonhospitalized (n = 131,915),
hospitalized (n = 16,764), those admitted to intensive care (n = 5,389) and
contemporary control cohort (n = 5,606,761). Adjusted HRs (dots) and
95% (error bars) CIs are presented, as are estimated excess burdens (bars)
and 95% CIs (error bars). Burdens are presented per 1,000 persons at 12
months of follow up. The dashed line marks a HR of 1.00; lower limits of
95% CIs with values greater than 1.00 indicate significantly increased risk.

(including covariate specification and weighting method) and the
same set of prespecified outcomes. Consistent with our pretest
expectations, the results showed that receipt of influenza vaccination
in odd-numbered calendar days versus even-numbered calendar
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days was not significantly associated with any of the prespecified
neurologic outcomes (Supplementary Table 16).

Discussion

In this study involving 154,068 people who had COVID-19,
5,638,795 contemporary controls and 5,859,621 historical controls,
which altogether correspond to 14,064,985 person-years of follow
up, we show that beyond the first 30 days of infection, people with
COVID-19 are at increased risk of an array of neurologic disorders
spanning several disease categories including stroke (both ischemic
and hemorrhagic), cognition and memory disorders, peripheral
nervous system disorders, episodic disorders, extrapyramidal and
movement disorders, mental health disorders, musculoskeletal disorders, sensory disorders and other disorders including Guillain–
Barré syndrome, and encephalitis or encephalopathy. The risks and
burdens were evident in subgroups based on age, race, sex, obesity,
smoking, ADI, diabetes, chronic kidney disease, hyperlipidemia,
hypertension or immune dysfunction. The risks were evident even
in people who did not need hospitalization during the acute phase of
the infection and increased according to the care setting of the acute
phase of the disease from nonhospitalized to hospitalized to admitted to intensive care. The findings were consistent in comparisons
involving the contemporary control group and the historical control
group. The results were robust to challenge in sensitivity analyses;
the application of negative-exposure and negative-outcome controls
yielded results consistent with prior expectations. Altogether, our
results show that the risks and burdens of neurologic disorders in
the COVID-19 group at 12 months are substantial. The long-term
consequences of SARS-CoV-2 infection should be taken into
account in devising policies for managing the ongoing pandemic,
and developing exit strategies for a postpandemic era. Health systems should consider these findings in capacity planning and in
designing clinical care pathways to address the care needs of people
who survive the acute phase of COVID-19.
More than 2 years into the COVID-19 global pandemic, it is
abundantly clear that infection with SARS-CoV-2 may result in a
broad array of long-term disorders9–14. Our report adds to this growing body of evidence by providing a comprehensive account of the
neurologic consequences of COVID-19 at 12 months. Given the
colossal scale of the pandemic, and even though the absolute numbers reported in this work are small, these may translate into a large
number of affected individuals around the world—and this will
likely contribute to a rise in the burden of neurologic diseases. This
places more emphasis on the continued need for multipronged primary prevention strategies through nonpharmaceutical interventions (for example, masking) and vaccines to reduce—to the extent
possible—the risk of contracting SARS-CoV-2. There is also an
urgent need to develop long-term sustainable strategies to prevent
mass infection with SARS-CoV-2 and to determine whether and
how these long-term neurologic (and other) complications could be
prevented or otherwise mitigated in people who are already infected
with SARS-CoV-2.
Governments and health systems should take into account the
findings that SARS-CoV-2 leads to long-term neurologic (and other
serious) consequences when devising policy for continued management of this pandemic and developing plans for a postpandemic
world. Some of the neurologic disorders reported here are serious
chronic conditions that will impact some people for a lifetime. These
conditions require early identification and care to reduce the risk of
further downstream adverse outcomes. The added burden of new
(incident) neurologic disease (and other incident long-term disorders) that result as a consequence of infection with SARS-CoV-2
will likely have profound ramifications not only on patients’ quality
of life and life expectancy but also on health systems and economic
productivity; these also risk widening inequities15. It is imperative
that we recognize the enormous challenges posed by Long Covid

and all its downstream long-term consequences. Meeting these
challenges requires urgent and coordinated—but so far absent—
global, national and regional response strategies16,17.
Our estimates of the risk of cerebrovascular disorders are generally consistent with our prior report (which was focused on investigating cardiovascular outcomes and included cerebrovascular
disorders); minor differences in estimates of risk and burden are
likely due to updated analytic approach and the longer follow up
time (generally 60 more days of follow up in this current study)18.
Our analyses by age as a continuous variable reveal two key findings. (1) Regardless of age and across the age spectrum, people with
COVID-19 had a higher risk of all the neurologic outcomes examined in this analysis. (2) Our interaction analyses suggest that the
effect of COVID-19 on risk of memory and cognitive disorders, sensory disorders and other neurologic disorders (including Guillain–
Barré syndrome and encephalitis or encephalopathy) is stronger in
younger adults; the effects of these disorders on younger lives are
profound and cannot be overstated; urgent attention is needed to
better understand these long-term effects and the means to mitigate them. Equally troubling is the stronger effect of COVID-19
on mental health disorders, musculoskeletal disorders and episodic
disorders in older adults, highlighting their vulnerability to these
disorders following SARS-CoV-2 infection.
Several mechanisms have been proposed to explain the postacute sequelae of COVID-19; these include persistence of the
virus, RNA fragments or viral proteins leading to continued activation of the immune system and chronic inflammation; other
mechanisms may involve autoimmunity, microbiome dysbiosis
and organ injury during the acute phase that may result in postacute manifestations19–25. The neurologic manifestations of Long
Covid are hypothesized to be driven by neuro-inflammation with
trafficking of immune cells (T cells and natural killer cells), cytokines and antibodies to the brain parenchyma resulting in activation
of microglia and astrocytes, disturbances in synaptic signaling of
upper-layer excitatory neurons, impaired neurogenesis and neuroblast formation, loss of oligodendrocytes and reduced myelinated
axon density22,23,26. Other mechanisms may involve endothelial cell
injury, complement activation and complement-mediated coagulopathy and microangiopathy leading to microbleeds or microclots27–29. Evidence from brain lysates of people with COVID-19
(compared with noninfected controls) demonstrates upregulation
of transforming-growth-factor-beta signaling, hyperphosphorylation and posttranslational modification of receptor and channel
proteins typically linked to Alzheimer’s disease30. Direct invasion of
the virus into the central nervous system has also been proposed as
a putative hypothetical mechanism of neuronal injury22. Evidence
also suggests significant structural brain changes in the postacute
phase of COVID-19; analyses of neuro-imaging data pre- and 4
to 5 months postinfection with SARS-CoV-2 reveal significant
longitudinal effects—even in mild cases—including reduction in
gray-matter thickness, increased activity of markers of tissue damage and reduction in global brain size2. Because of the broad nature
of the neurologic sequelae of SARS-CoV-2, various—and not necessarily mutually exclusive—mechanisms may be at play for different
neurologic disorders; these mechanisms may accelerate progression
of pre-existing subclinical disease or result in de novo disease31.
This study has several strengths. We leveraged the breadth and
depth of the national healthcare databases of the US Department
of Veterans Affairs to build a large cohort of 154,068 people who
had COVID-19 and more than 11 million people in the control
group. We investigated a comprehensive list of prespecified neurologic outcomes. We used both predefined (based on established
knowledge) and—in recognition of our incomplete and evolving
knowledge of COVID-19—an expanded set of 100 algorithmically
selected covariates in several data domains including diagnostic
codes, prescription records and laboratory test results to balance
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the exposure groups and estimate the risk and burden of neurologic
disorders at 12 months. We examined the associations in clinically important subgroups and across the spectrum of care during
the acute phase of COVID-19 (nonhospitalized, hospitalized and
admitted to intensive care). We investigated these associations in
COVID-19 versus a contemporary cohort exposed to the broader
contextual changes brought on by the pandemic, and a historical
cohort from an era undisturbed by the pandemic. We subjected our
analyses to the scrutiny of multiple sensitivity analyses and successfully demonstrated testing of negative-exposure and outcome controls. Finally, we provide two measures of risk: (1) hazard ratios on
the relative scale; and (2) excess burden on absolute scale. The latter
also incorporates the contribution of baseline risk and is useful to
understand and contextualize the broader impact of the relative risk
on the population.
This study has several limitations. The demographic characteristics of the study population (majority White and male) may
limit generalizability of findings. Although we adjusted—through
weighting—for predefined and algorithmically selected covariates,
and although we used validated definitions for outcomes, and our
results were robust to challenge in sensitivity analyses and survived
the scrutinous application of negative controls, we cannot completely rule out misclassification bias or residual confounding. Our
contemporary control included people who had no evidence of
SARS-CoV-2 infection; it is possible that some people had an infection but were not tested for it; these people will have been enrolled in
the control group; and if present in large numbers, this may bias the
results toward the null and lead to underestimation of risk. While
results from inverse probability weighting may be sensitive to different specifications of the weighting processes32–35, we triangulated
several approaches to model specification in our sensitivity analyses
and all yielded consistent results. Because we aimed to examine outcomes at 12 months, our cohorts were enrolled before 15 January
2021 (before SARS-CoV-2 vaccines were widely available in the
US), and less than 1% of people in the COVID-19 group and contemporary control group were vaccinated before T0. Our subgroup
analyses were designed to estimate the risk of outcomes in each
subgroup, the strength of the association for any specific outcome
may not be necessarily comparable across subgroups. Finally, the
pandemic remains a highly dynamic global event; as new variants
of SARS-CoV-2 emerge, as vaccine uptake improves, as therapeutics for acute COVID-19 (monoclonal antibodies, antiviral agents)
become more available, it is possible that the epidemiology of the
long-term sequelae of SARS-CoV-2 infection (including long-term
neurologic sequelae) may also change over time36.
In conclusion, our report provides a comprehensive analysis
of neurologic outcomes at 12 months. We show increased risk of
an array of neurologic disorders spanning several neurologic disease categories including stroke (both ischemic and hemorrhagic),
cognition and memory disorders, peripheral nervous system disorders, episodic disorders, extrapyramidal and movement disorders, mental health disorders, musculoskeletal disorders, sensory
disorders, and other disorders including Guillain–Barré syndrome,
and encephalitis or encephalopathy. The risks were evident in all
examined subgroups and were evident even in people who were not
hospitalized during the acute phase of the disease. Altogether, the
findings call for attention to the long-term neurologic consequences
of SARS-CoV-2 infection. Both healthcare system planning, and
more broadly, public policy making, should take into account the
long-term neurologic (and other) consequences of infection with
SARS-CoV-2.
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Methods

Ethics statement. This study was approved by the institutional review board of
the VA St. Louis Health Care System, which granted a waiver of informed consent
(protocol number 1606333).
Setting. This study was conducted using the electronic healthcare databases of the
US Department of Veterans Affairs. The VHA—a branch of the US Department
of Veterans Affairs—operates the largest nationally integrated healthcare system
within the US consisting of 1,255 healthcare facilities (including 170 VA healthcare
systems and 1,074 outpatient sites). All veterans enrolled in the VHA have access
to a comprehensive medical benefit package, including preventative and health
maintenance, outpatient care, inpatient hospital care, prescriptions, mental
healthcare, home healthcare, primary care, specialty care, geriatric and extended
care, medical equipment and prosthetics. VA electronic healthcare databases are
updated daily.
Cohort. A flowchart of cohort construction is provided in Fig. 1. Veterans who
were users of the VHA in 2019 (n = 6,244,069) and had a positive COVID-19
test between 1 March 2020 and 15 January 2021 were selected for the COVID19 cohort (n = 169,476). To facilitate the examination of postacute COVID-19
outcomes, we further selected those who were alive 30 days after the positive test
result from the COVID-19 cohort (n = 154,068). The date of the first COVID-19
positive test served as T0 and marked the start of follow up; follow up ended on 31
December 2021.
We then constructed a contemporary control group consisting of veterans
who were users of the VHA in 2019 (n = 6,244,069). Those who were alive by 1
March 2020 (n = 5,963,205) and were not already part of the COVID-19 cohort
were selected for the contemporary control cohort (n = 5,809,137). The start
of follow up of participants in the contemporary control cohort was randomly
assigned following the same distribution of the date of a positive COVID-19
test result in the COVID-19 group so that the proportion of participants with a
start of follow up on a certain date was the same in both groups; this ensures a
similar distribution of follow-up time between the COVID-19 and contemporary
control cohorts. At the start of follow up, 5,660,999 participants were alive. Those
alive after 30 days after the start of follow up (n = 5,638,795) were selected as the
contemporary control cohort. Follow up ended on 31 December 2021.
We also constructed a historical control group composed of 6,463,487
participants who were users of the VHA in 2017. From the 6,152,185 participants
who were alive on 1 March 2018, 6,009,794 participants who were not already
part of the COVID-19 group were enrolled into the historical control group.
We randomly assigned T0 in the historical control group using the follow-up
distribution of T0 in the COVID-19 group minus 2 years (730 days); this ensured
a similar distribution of follow-up time between the COVID-19 and historical
control cohorts. Overall, 5,876,880 participants in the historical control group were
alive at T0; the final historical control group consisted of 5,859,621 participants that
were alive 30 days after T0. End of follow up for the historical control group was set
as 31 December 2019.
Data sources. This study used electronic health records from the VA Corporate
Data Warehouse (CDW). The CDW Patient domain provided patient demographic
information. Outpatient clinical information was collected from the CDW
Outpatient Encounters domain; clinical information during hospitalization was
obtained from the CDW Inpatient Encounters domain. The CDW Outpatient
Pharmacy and CDW Barcode Medication Administration domains provided
information about medication prescriptions and fillings. Laboratory test
information was gathered from the CDW Laboratory Results domain, and the
COVID-19 Shared Data Resource provided information relevant to COVID-19.
We also used the ADI, a summary measure of income, education, employment
and housing, as a composite variable of contextual factors present at a participant’s
residential location37.
Prespecified outcomes. The prespecified outcomes were selected based on
our earlier work on the systematic characterization of Long Covid1,10,14 and
evidence from previous literature38–44. Each neurologic outcome was defined,
based on the corresponding International Classification of Diseases, 10th revision
(ICD10) diagnostic codes1,9–12,38–44. Codes are available on GitHub. Individual
outcomes were also aggregated into a related composite outcome (for example,
cerebrovascular disorders consisted of an aggregation of ischemic stroke,
hemorrhagic stroke, cerebral venous thrombosis and TIAs). Additionally, we
specified the composite of any neurologic outcome defined as the first incident
occurrence of any of the predefined neurologic outcomes examined in this study.
Incident individual and composite neurologic outcomes during the postacute
phase of COVID-19 were assessed during the follow-up period between the
30 days after T0 until the end of follow up in those without any history of the
specified outcome in the year before T0.
Covariates. In recognition that our knowledge of COVID-19 is evolving and
incomplete, we used a dual-pronged approach to identify covariates: (1) we
selected covariates based on previous knowledge1,3,5–13,22,36,45–49; (2) we used an
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algorithmic approach to identify covariates in several data domains including
diagnoses, medications and laboratory test results. Both predefined and
algorithmically selected covariates were used in the modeling and were assessed
in the year before T0.
Predefined covariates included age, race (White, Black and other), sex, ADI,
body mass index, smoking status (current, former and never) and measures of
healthcare utilization (number of outpatient and inpatient encounters as well
as long-term care utilization)1,36. Several comorbidities were also selected as
predefined variables, including cancer, chronic kidney disease, chronic lung
disease, diabetes and hypertension. Additional covariates included estimated
glomerular filtration rate and systolic and diastolic pressure. Continuous variables
were transformed into restricted cubic spline function to account for potential
nonlinear relationships.
Our predefined covariates were also supplemented by algorithmically
selected covariates from high-dimensional data domains including diagnoses,
medications and laboratory test results50. All information used for algorithmically
selected covariates was collected within 1 year before the exposure. This was
achieved by gathering all patient encounter, prescription and laboratory data and
categorizing the information into 540 diagnostic groups, 543 medication types and
62 laboratory test abnormalities. We selected variables from these data domains
(diagnoses, medications and laboratory test results) which occurred in at least 100
participants within each of the exposure groups—this was done in recognition
that variables that are exceedingly rare (occur in less than 100 participants in these
large cohorts) may not materially influence the examined associations. We then
estimated the univariate relative risk between each variable and the exposure. The
top 100 variables with the highest relative risk were selected51. This algorithmic
selection process for high-dimensional covariates was conducted independently for
each outcome-specific cohort.
Statistical analyses. Baseline characteristics in the COVID-19, contemporary and
historical control groups and standardized mean differences were described.
We estimated the risk of each incident neurologic outcome by first building a
subcohort of participants without a history of the outcome of interest (for example,
the risk of incident stroke was estimated within a subcohort of participants without
history of stroke in the year before cohort enrollment). For each subcohort,
multinomial logistic regression was built to estimate the probability of a participant
belonging to the observed group (COVID-19, contemporary control and historical
control group) conditional on all predefined covariates listed in the covariate
section and algorithmically selected high-dimensional variables denoted by L
(ref. 52). The estimated probability (P(group = observed group|L)) was used as the
propensity score to calculate the inverse probability weight for average treatment
effect within the cohort. The stabilized inverse probability weight was computed as
P(group = observed group)/P(group = observed group|L), where L is the covariates,
P(group = observed group) is the group proportion within the cohort and served
as the stabilization factor53. To further reduce the influence of extreme weights,
the stabilized weights were truncated at 30 (refs. 32,33,35). Less than 0.001% of the
stabilized weights were greater than 30 and were truncated. After application of
weighting, covariate balance was assessed by standardized mean differences.
We then used cause-specific hazard models where death was considered as a
competing risk to estimate hazard ratios of incident neurologic outcomes between
the COVID-19 and contemporary cohorts and the COVID-19 and historical
cohorts after application of inverse probability weights. The burdens per 1,000
participants at 12 months of follow up in the COVID-19 and control groups were
estimated based on the survival probability at 12 months within each group;
excess burdens were computed based on the difference of the estimated burdens
between COVID-19 and control groups. Additionally, we conducted analyses in
subgroups based on participant age, race, sex, obesity, smoking, ADI, diabetes,
chronic kidney disease, hyperlipidemia, hypertension and immune dysfunction
statuses. To further understand the association between COVID-19 and incident
neurologic outcomes across age, we conducted spline analyses, where age was
treated as restricted cubic spline with knots placed at the 10th, 35th, 65th and 90th
percentiles. We also performed interaction analyses between age and COVID-19
exposure to examine whether age modified the association between COVID-19
and outcomes.
The association between COVID-19 and risks of postacute neurologic
outcomes was evaluated in mutually exclusive groups based on participants’ care
setting during the acute phase of COVID-19 infection (that is, whether participants
were nonhospitalized, hospitalized or admitted into the intensive care unit
during the first 30 days of infection). Using the approach outlined in the previous
paragraph, inverse probability weights were estimated for each care setting group.
Cause-specific hazard models with inverse probability weighting were applied, and
HRs, burdens and excess burdens were calculated.
To further test the robustness of our study design, we conducted multiple
sensitivity analyses. (1) We modified our covariate selection by restricting
covariate inclusion to only predefined variables when constructing the inverse
probability weight (that is, we did not include any algorithmically selected
covariates). (2) Alternatively, we applied a doubly robust approach, in which
associations were estimated by applying both covariates adjustment and the
inverse probability weights to survival models14.
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To examine whether our approach would reproduce known associations,
we tested the outcome of fatigue—a signature sequela of Long Covid—as a
positive outcome control. To further test the rigor of our approach, we tested a
battery of negative-outcome controls, for which no prior evidence supports the
existence of a causal relationship between COVID-19 exposure and any of these
negative-outcome controls53. We also tested a pair of negative-exposure controls.
We hypothesized that exposure to the influenza vaccine in odd-numbered or
even-numbered calendar days between 1 March 2020 and 15 January 2021 would
be associated with similar risks of all the neurologic outcomes examined in our
analyses. Successful application of these negative outcomes and negative-exposure
controls might reduce concern about the presence of spurious biases related to
study design, covariate selection, analytic approach, outcome ascertainment,
residual confounding and other potential sources of latent biases53.
Robust sandwich variance estimators were used to provide an estimation
of variance when applying weightings. In all analyses, evidence of statistical
significance was considered when a 95% CI excluded unity. All analyses were
conducted using SAS Enterprise Guide v.8.2 (SAS Institute), and visualization of
results was accomplished using R v.4.04.
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.
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Extended Data Fig. 1 | Standardized mean difference of predefined and algorithmically selected high-dimensional variables. Standardized mean
difference between COVID-19 and contemporary control.
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Extended Data Fig. 2 | The risks of incident postacute COVID-19 composite neurologic outcomes across age compared with the contemporary control
cohort. Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke, and cerebral venous thrombosis),
cognition and memory (memory problems and Alzheimer’s disease), disorders of the peripheral nerves (peripheral neuropathy, paresthesia,
dysautonomia, and Bell’s palsy), episodic disorders (migraine, epilepsy and seizures, and headache disorders), extrapyramidal and movement disorders
(abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress
and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia, and myopathy), sensory disorders
(Hearing abnormalities or tinnitus, vision abnormalities, loss of smell, and loss of taste), other neurologic or related disorders (dizziness, somnolence,
Guillain-Barré syndrome, encephalitis or encephalopathy and transverse myelitis), and any neurologic outcome (incident occurrence of any neurologic
outcome studied). Outcomes were ascertained 30d after the COVID-19-positive test until the end of follow up. COVID-19 cohort (n = 154,068) and
contemporary control cohort (n = 5,638,795). Age was transformed into restricted cubic spline function for the analyses. P value was based on 2-sided
Wald Chi-Squared test on interaction between age and exposure, without multiple comparisons adjustment. A P value of <0.05 suggests that age modifies
the association between COVID-19 and the neurologic outcome. The P value for cerebrovascular disorders=0.38, cognition and memory disorders=0.001,
disorders of the peripheral nerves=0.15, episodic disorders<0.001, extrapyramidal and movement disorders=0.88, mental health disorders<0.001,
musculoskeletal disorders<0.001, sensory disorders<0.001, other neurologic or related disorders<0.001, and any neurologic disorder=0.003.
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Extended Data Fig. 3 | Standardized mean difference of predefined and algorithmically selected high-dimensional variables. (a) by care setting of the
acute infection between COVID-19 and contemporary control; (b) between COVID-19 and historical control; (c) by care setting of the acute infection
between COVID-19 and historical control.
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Extended Data Fig. 4 | See next page for caption.
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Extended Data Fig. 4 | Risks and 12-month burdens of incident postacute COVID-19 neurologic outcomes compared with the historical control cohort.
Outcomes were ascertained 30 d after the COVID-19-positive test until the end of follow-up. COVID-19 cohort (n = 154,068) and historical control cohort
(n = 5,859,621). Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess burdens (bars) and 95% confidence intervals (error
bars). Burdens are presented per 1000 persons at 12 months of follow up. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater
than 1.00 indicate significantly increased risk.

Nature Medicine | www.nature.com/naturemedicine

NATURE MEDICInE

Articles

Extended Data Fig. 5 | Risks and 12-month burdens of incident postacute COVID-19 composite neurologic outcomes compared with the historical
control cohort. Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke, and cerebral venous
thrombosis), cognition and memory (memory problems and Alzheimer’s disease), disorders of the peripheral nerves (peripheral neuropathy, paresthesia,
dysautonomia, and Bell’s palsy), episodic disorders (migraine, epilepsy and seizures, and headache disorders), extrapyramidal and movement disorders
(abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress
and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia, and myopathy), sensory disorders
(Hearing abnormalities or tinnitus, vision abnormalities, loss of smell, and loss of taste), other neurologic or related disorders (dizziness, somnolence,
Guillain-Barré syndrome, encephalitis or encephalopathy and transverse myelitis), and any neurologic outcome (incident occurrence of any neurologic
outcome studied). Outcomes were ascertained 30d after the COVID-19-positive test until the end of follow up. COVID-19 cohort (n = 154,068) and
historical control cohort (n = 5,859,621). Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess burdens (bars) and 95%
confidence intervals (error bars). Burdens are presented per 1000 persons at 12 months of follow up. The dashed line marks a HR of 1.00; lower limits of
95% CIs with values greater than 1.00 indicate significantly increased risk.
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Extended Data Fig. 6 | Subgroup analyses of the risks of incident postacute COVID-19 composite neurologic outcomes compared with the
historical control cohort. Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke, and cerebral venous
thrombosis), cognition and memory (memory problems and Alzheimer’s disease), disorders of the peripheral nerves (peripheral neuropathy, paresthesia,
dysautonomia, and Bell’s palsy), episodic disorders (migraine, epilepsy and seizures, and headache disorders), extrapyramidal and movement disorders
(abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress
and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia, and myopathy), sensory disorders
(Hearing abnormalities or tinnitus, vision abnormalities, loss of smell, and loss of taste), other neurologic or related disorders (dizziness, somnolence,
Guillain-Barré syndrome, encephalitis or encephalopathy and transverse myelitis), and any neurologic outcome (incident occurrence of any neurologic
outcome studied). Outcomes were ascertained 30d after the COVID-19-positive test until the end of follow up. COVID-19 cohort (n = 154,068) and
historical control cohort (n = 5,859,621). Adjusted HRs (dots) and 95% (error bars) CIs are presented. The dashed line marks a HR of 1.00; lower limits of
95% CIs with values greater than 1.00 indicate significantly increased risk.
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Extended Data Fig. 7 | The risks of incident postacute COVID-19 composite neurologic outcomes across age compared with the historical control
cohort. Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke, and cerebral venous thrombosis),
cognition and memory (memory problems and Alzheimer’s disease), disorders of the peripheral nerves (peripheral neuropathy, paresthesia,
dysautonomia, and bell’s palsy), episodic disorders (migraine, epilepsy and seizures, and headache disorders), extrapyramidal and movement disorders
(abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress
and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia, and myopathy), sensory disorders
(Hearing abnormalities or tinnitus, vision abnormalities, loss of smell, and loss of taste), other neurologic or related disorders (dizziness, somnolence,
Guillain-Barré syndrome, encephalitis or encephalopathy and transverse myelitis), and any neurologic outcome (incident occurrence of any neurologic
outcome studied). Outcomes were ascertained 30d after the COVID-19-positive test until the end of follow up. COVID-19 cohort (n = 154,068) and
historical control cohort (n = 5,859,621). Age was transformed into restricted cubic spline function for the analyses. P value was based on 2 sided Wald
Chi-Squared test on interaction between age and exposure, without multiple comparisons adjustment. A P value of <0.05 suggests that age modifies the
association between COVID-19 and the neurologic outcome. The P value for cerebrovascular disorders=0.57, cognition and memory disorders=0.009,
disorders of the peripheral nerves=0.04, episodic disorders<0.001, extrapyramidal and movement disorders=0.05, mental health disorders<0.001,
musculoskeletal disorders<0.001, sensory disorders<0.001, other neurologic or related disorders=0.002, and any neurologic disorder<0.001.
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Extended Data Fig. 8 | See next page for caption.
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Extended Data Fig. 8 | Risks and 12-month burdens of incident postacute COVID-19 neurologic outcomes by care setting of the acute infection
compared with the historical control cohort. Risks and burdens were assessed at 12 months in mutually exclusive groups comprising nonhospitalized
individuals with COVID-19 (green), individuals hospitalized for COVID-19 (orange) and individuals admitted to intensive care for COVID-19 during the
acute phase (first 30 d) of COVID-19 (purple). Outcomes were ascertained 30 d after the COVID-19-positive test until the end of follow up. The historical
control cohort served as the referent category. Within the COVID-19 cohort, nonhospitalized (n = 131,915), hospitalized (n = 16,764), admitted to intensive
care (n = 5,389) and historical control cohort (n = 5,809,908). Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess
burdens (bars) and 95% confidence intervals (error bars). Burdens are presented per 1000 persons at 12 months of follow up. The dashed line marks a HR
of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.
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Extended Data Fig. 9 | Risks and 12-month burdens of incident postacute COVID-19 composite neurologic outcomes by care setting of the acute
infection compared with the historical control cohort. Risks and burdens were assessed at 12 months in mutually exclusive groups comprising
nonhospitalized individuals with COVID-19 (green), individuals hospitalized for COVID-19 (orange) and individuals admitted to intensive care for
COVID-19 during the acute phase (first 30 d) of COVID-19 (purple). Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA,
hemorrhagic stroke, and cerebral venous thrombosis), cognition and memory (memory problems and Alzheimer’s disease), disorders of the peripheral
nerves (peripheral neuropathy, paresthesia, dysautonomia, and Bell’s palsy), episodic disorders (migraine, epilepsy and seizures, and headache disorders),
extrapyramidal and movement disorders (abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders
(major depressive disorders, stress and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia,
and myopathy), sensory disorders (Hearing abnormalities or tinnitus, vision abnormalities, loss of smell, and loss of taste), other neurologic or related
disorders (dizziness, somnolence, Guillain-Barré syndrome, encephalitis or encephalopathy and transverse myelitis), and any neurologic outcome
(incident occurrence of any neurologic outcome studied). Outcomes were ascertained 30 d after the COVID-19-positive test until the end of follow up. The
historical control cohort served as the referent category. Within the COVID-19 cohort, nonhospitalized (n = 131,915), hospitalized (n = 16,764), admitted
to intensive care (n = 5,389) and historical control cohort (n = 5,809,908). Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated
excess burdens (bars) and 95% confidence intervals (error bars). Burdens are presented per 1000 persons at 12 months of follow up. The dashed line
marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.
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